Clinical Utility of ClarityDX Prostate

Launched by NANOSTICS · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a tool called ClarityDX Prostate, which helps doctors assess the risk of patients having significant prostate cancer. By using a combination of blood test results (total and free PSA levels), a patient's age, and previous biopsy history, the ClarityDX Prostate tool can provide a risk score. This score helps doctors and patients decide if further tests like imaging or biopsies are necessary. The study aims to see if using ClarityDX Prostate can reduce unnecessary medical procedures for men suspected of having prostate cancer.

Eligible participants are men aged 18 and older who have been referred to a urology clinic due to concerns about prostate cancer and have never been diagnosed with prostate cancer before. Those who join the study will either receive the ClarityDX Prostate assessment or standard care. Throughout the trial, the researchers will look at various outcomes, including how it affects the number of negative biopsies and the overall healthcare resources used. If you or someone you know meets the eligibility criteria, participating in this study could provide valuable insights into prostate cancer detection and management.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Males ≥ 18 years of age
• • 2. Referred to urology for suspicion of prostate cancer
• • 3. No prior prostate cancer diagnosis
• • 4. Willing to participate in the study
• • 5. Availability for cancer care in the jurisdiction of recruitment
• Exclusion Criteria:
• • 1. Unwilling to participate in the study
• • 2. Unable to consent